TG Therapeutics, Inc.
TGTX
$28.64
$0.682.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 19.09% | 14.57% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 19.09% | 14.57% | |||
| Cost of Revenue | 35.77% | 48.34% | |||
| Gross Profit | 15.58% | 9.33% | |||
| SG&A Expenses | -0.99% | 14.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.36% | 24.49% | |||
| Operating Income | 71.95% | -15.72% | |||
| Income Before Tax | 74.04% | -16.21% | |||
| Income Tax Expenses | 106.04% | -13,454.77% | |||
| Earnings from Continuing Operations | -94.11% | 1,286.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -94.11% | 1,286.79% | |||
| EBIT | 71.95% | -15.72% | |||
| EBITDA | 71.92% | -15.70% | |||
| EPS Basic | -94.01% | 1,299.32% | |||
| Normalized Basic EPS | 76.93% | -15.41% | |||
| EPS Diluted | -94.21% | 1,329.41% | |||
| Normalized Diluted EPS | 75.75% | -15.39% | |||
| Average Basic Shares Outstanding | -1.69% | -0.90% | |||
| Average Diluted Shares Outstanding | -1.01% | -0.96% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||